RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration
Status:
Completed
Trial end date:
2019-06-26
Target enrollment:
Participant gender:
Summary
This is an open label, non-controlled, dose-escalating study assessing the safety,
tolerability, and bioactivity of a single intravitreal (i.vt.) injection of RBM-007 in
approximately nine subjects with exudative age-related macular degeneration.